申请人:BETTA PHARMACEUTICALS CO., LTD.
公开号:US20220402948A1
公开(公告)日:2022-12-22
The present invention relates to the compounds of Formula I, methods of using these compounds as EGFR inhibitors, and pharmaceutical compositions comprising compounds thereof. The compounds are used for treating, preventing or ameliorating diseases or disorders such as cancer or infections.
本发明涉及化合物I的配方、使用这些化合物作为EGFR抑制剂的方法,以及包含这些化合物的药物组合物。这些化合物可用于治疗、预防或改善诸如癌症或感染等疾病或障碍。